August 23, 2006 – Advanced Cell Therapeutics announced a non-controversial way to create stem cell lines; Merck said Arcoxia, its new Cox-2 inhibitor, did not cause more cardiovascular events than diclofenac; Theravance released positive data on its antibiotic telavancin; Mayne Pharma completed its purchase of two oncology drugs from SuperGen; Cytokinetics will begin a Phase I trial of a cardiac drug in healthy volunteers; Barrier Therapeutics launched its cold sore cream, Denavir, in Canada; Critical Therapeutics said an IV asthma drug passed a Phase I/II trial; UCB received FDA approval of Keppra as an adjunct therapy for seizures; and Dishman Pharma of India paid $75 million to buy three manufacturing facilities in Switzerland. The Centient Biotech 200™ fell 7.5 points to 3669.49, a loss of .20%. More details...
